MX2015007402A - Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. - Google Patents
Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.Info
- Publication number
- MX2015007402A MX2015007402A MX2015007402A MX2015007402A MX2015007402A MX 2015007402 A MX2015007402 A MX 2015007402A MX 2015007402 A MX2015007402 A MX 2015007402A MX 2015007402 A MX2015007402 A MX 2015007402A MX 2015007402 A MX2015007402 A MX 2015007402A
- Authority
- MX
- Mexico
- Prior art keywords
- human patient
- growth hormone
- clinically effective
- fusion
- albumin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000009027 Albumins Human genes 0.000 title 1
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
- 108091006905 Human Serum Albumin Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000009578 growth hormone therapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
La presente invención proporciona un método de tratamiento de un paciente humano en necesidad de terapia de la hormona de crecimiento mediante la administración periódica al paciente humano por más de dos semanas de una cantidad efectiva de una composición que comprende un vehículo farmacéuticamente aceptable y una proteína de fusión cuya secuencia de aminoácidos se establece como las SEQ ID NO: 1, a fin de tratar con ello el paciente humano. La presente invención también proporciona un método de tratamiento de un paciente humano en necesidad de terapia de la hormona de crecimiento mediante la administración al paciente humano, en un régimen clínicamente efectiva, de una dosis clínicamente efectiva de una composición que comprende un vehículo farmacéuticamente aceptable y una proteína de fusión cuyo secuencia de aminoácidos se expone como SEQ ID NO: 1, en donde la dosis clínicamente efectiva y el régimen clinicamente efectiva son seleccionados por una serie de pasos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736267P | 2012-12-12 | 2012-12-12 | |
| PCT/US2013/074145 WO2014093354A1 (en) | 2012-12-12 | 2013-12-10 | Fusion of human growth hormone and albumin, formulation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007402A true MX2015007402A (es) | 2015-09-23 |
Family
ID=50881605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007402A MX2015007402A (es) | 2012-12-12 | 2013-12-10 | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140162954A1 (es) |
| EP (1) | EP2931298A4 (es) |
| JP (1) | JP2016508125A (es) |
| KR (1) | KR20150106887A (es) |
| AR (1) | AR093908A1 (es) |
| AU (1) | AU2013359550A1 (es) |
| CA (1) | CA2892626A1 (es) |
| EA (1) | EA201591108A1 (es) |
| HK (1) | HK1216007A1 (es) |
| IL (1) | IL238897A0 (es) |
| MX (1) | MX2015007402A (es) |
| WO (1) | WO2014093354A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113359A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
| WO2016011281A1 (en) * | 2014-07-17 | 2016-01-21 | Teva Pharmaceutical Industries Ltd. | FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN |
| WO2017136583A1 (en) * | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| JOP20190019A1 (ar) * | 2016-08-30 | 2019-02-12 | Genexine Inc | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) |
| JP7216075B2 (ja) | 2017-08-24 | 2023-01-31 | サノフイ | 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置 |
| CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020156019A1 (en) * | 2001-04-20 | 2002-10-24 | Renasci, Inc., D/B/A Renasci Anti-Aging Center | Method of optimizing growth hormone replacement |
| US20020155990A1 (en) * | 2001-04-20 | 2002-10-24 | Renasci, Inc., D/B/A Renasci Anti-Aging Center | Method of optimizing growth hormone replacement |
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| PT1463751E (pt) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| CN101022820A (zh) * | 2004-08-30 | 2007-08-22 | 特西卡股份有限公司 | 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置 |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
-
2013
- 2013-12-10 EA EA201591108A patent/EA201591108A1/ru unknown
- 2013-12-10 MX MX2015007402A patent/MX2015007402A/es unknown
- 2013-12-10 EP EP13861675.0A patent/EP2931298A4/en not_active Withdrawn
- 2013-12-10 CA CA2892626A patent/CA2892626A1/en not_active Abandoned
- 2013-12-10 KR KR1020157018674A patent/KR20150106887A/ko not_active Application Discontinuation
- 2013-12-10 AR ARP130104617A patent/AR093908A1/es unknown
- 2013-12-10 WO PCT/US2013/074145 patent/WO2014093354A1/en active Application Filing
- 2013-12-10 JP JP2015547472A patent/JP2016508125A/ja not_active Ceased
- 2013-12-10 AU AU2013359550A patent/AU2013359550A1/en not_active Abandoned
- 2013-12-10 US US14/101,632 patent/US20140162954A1/en not_active Abandoned
-
2015
- 2015-05-19 IL IL238897A patent/IL238897A0/en unknown
-
2016
- 2016-04-07 HK HK16103946.1A patent/HK1216007A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238897A0 (en) | 2015-07-30 |
| AU2013359550A1 (en) | 2015-07-23 |
| EP2931298A1 (en) | 2015-10-21 |
| EA201591108A1 (ru) | 2015-11-30 |
| US20140162954A1 (en) | 2014-06-12 |
| HK1216007A1 (zh) | 2016-10-07 |
| WO2014093354A1 (en) | 2014-06-19 |
| CA2892626A1 (en) | 2014-06-19 |
| KR20150106887A (ko) | 2015-09-22 |
| AR093908A1 (es) | 2015-06-24 |
| JP2016508125A (ja) | 2016-03-17 |
| EP2931298A4 (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| ES2397889A1 (es) | PÉPTIDOS MODULADORES DE PGC-1Alfa. | |
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| MX336187B (es) | Metodo para tratar el mal de parkinson. | |
| NZ602471A (en) | Antagonists of activin-actriia and uses for increasing red blood cell levels | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| MX338554B (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| IN2014DN06920A (es) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| MX349364B (es) | Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. | |
| RU2015121574A (ru) | Препарат для биспецифических активаторов т-клеток(bite) |